4,317 Merck & Co., Inc. $MRK Shares Sold by Harbour Investments Inc.

Harbour Investments Inc. trimmed its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 10.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,049 shares of the company’s stock after selling 4,317 shares during the period. Harbour Investments Inc.’s holdings in Merck & Co., Inc. were worth $5,238,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Round Rock Advisors LLC lifted its stake in shares of Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after buying an additional 66 shares during the period. Cypress Wealth Services LLC lifted its stake in shares of Merck & Co., Inc. by 0.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after purchasing an additional 69 shares during the period. Code Waechter LLC boosted its holdings in shares of Merck & Co., Inc. by 3.4% during the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after purchasing an additional 71 shares during the last quarter. Quest 10 Wealth Builders Inc. grew its position in shares of Merck & Co., Inc. by 12.2% in the third quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock valued at $102,000 after purchasing an additional 76 shares during the period. Finally, Cascade Financial Partners LLC grew its position in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after purchasing an additional 80 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on MRK shares. Jefferies Financial Group upped their target price on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 7th. Freedom Broker increased their price objective on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the stock a “hold” rating in a report on Monday, November 2nd. Argus began coverage on shares of Merck & Co., Inc. in a report on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. Finally, UBS Group raised their target price on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $155.74.

Get Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $144.49 on Tuesday. Merck & Co., Inc. has a twelve month low of $92.11 and a twelve month high of $156.92. The stock has a market capitalization of $356.20 billion, a P/E ratio of 148.96, a PEG ratio of 6.74 and a beta of 0.13. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The business’s fifty day moving average price is $146.04 and its 200 day moving average price is $128.80.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.09 by $0.40. The company had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.58 earnings per share. As a group, research analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current year.

Insider Activity

In other news, EVP Richard Deluca sold 58,185 shares of the business’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the completion of the sale, the executive vice president owned 112,955 shares in the company, valued at approximately $16,718,469.55. The trade was a 34.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.17% of the company’s stock.

About Merck & Co., Inc.

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.